McMaster University

Michael G. DeGroote
National Pain Centre

Scope of Search

Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain

Appendix B: Reference List

  1. Adams NJ, Plane MB, Fleming MF, Mundt MP, Saunders LA, Stauffacher EA. Opioids and the treatment of chronic pain in a primary care sample. J Pain Symptom Manage 2001 Sep;22(3):791-6. (GRADE B, Supports Recommendation 17).
  2. Adlaf EM, Paglia-Boak A, Brands B. Use of OxyContin by adolescent students. CMAJ 2006 Apr 25;174(9):1303- (GRADE B, Supports Recommendation 18).
  3. Alattar MA, Scharf SM. Opioid-associated central sleep apnea: A case series. Sleep and Breathing 2009;13(2):201-6. (GRADE B, Supports Recommendation 10).
  4. Amar PJ, Schiff ER. Acetaminophen safety and hepatotoxicity--where do we go from here? Expert Opin Drug Saf 2007 Jul;6(4):341-55.
  5. Arkinstall W, Sandler A, Goughnour B, Babul N, Harsanyi Z, Darke AC. Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial. Pain 1995 Aug;62(2):169-78. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  6. Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. American Journal of Medicine 2006 Apr;119(4):292-6.
  7. Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr Opin Gastroenterol 2007 May;23(3):244-54.
  8. Babul N, Noveck R, Chipman H, Roth SH, Gana T, Albert K. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004 Jul;28(1):59-71. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  9. Baillargeon L, Landreville P, Verreault R, Beauchemin JP, Gregoire JP, Morin CM. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ 2003;169(10):1015-20. (GRADE A, Supports Recommendation 6).
  10. Ballantyne JC, Mao J. Opioid therapy for chronic pain. New England Journal of Medicine 349(20):1943-53, 2003 Nov 13.
  11. Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 2007 Jun;129(3):235-55.
  12. Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. Journal of Opioid Management 2006 Sep;2(5):277-82. (GRADE B, Supports Recommendation 13).
  13. Barry DT, Moore BA, Pantalon MV, Chawarski MC, Sullivan LE, O'Connor PG, et al. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med 2007;22(2):242-5. (GRADE B, Supports Recommendation 21).
  14. Beaulieu AD, Peloso PM, Haraoui B, Bensen W, Thomson G, Wade J, et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Res Manag 2008 Mar;13(2):103-10. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  15. Becker N, Sjogren P, Bech P, Olsen AK, Eriksen J. Treatment outcome of chronic non-malignant pain patients managed in a danish multidisciplinary pain centre compared to general practice: a randomised controlled trial. Pain 2000 Feb;84(2-3):203-11. (GRADE A, Supports Recommendation 13 and Recommendation 16).
  16. Becker WC, Fiellin DA. Provider Satisfaction with Office-Based Treatment of Opioid DependenceA Systematic Review. Subst Abus 2006;26(1):15-22. (GRADE B, Supports Recommendation 21).
  17. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug & Alcohol Dependence 2008 Apr 1;94(1-3):38-47. (GRADE B, Supports Recommendation 1 and Recommendation 20).
  18. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine 2003 May;114(7):537-45. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  19. Bhamb B, Brown D, Hariharan J, Anderson J, Balousek S, Fleming MF. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Current Medical Research & Opinion 2006 Sep;22(9):1859-65.
  20. Bieber CM, Fernandez K, Borsook D, Brennan MJ, Butler SF, Jamison RN, et al. Retrospective accounts of initial subjective effects of opioids in patients treated for pain who do or do not develop opioid addiction: a pilot case-control study. Experimental & Clinical Psychopharmacology 2008 Oct;16(5):429-34. (GRADE B, Supports Recommendation 11).
  21. Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain 2009;142(3):179-82.
  22. Blinick G, Wallach RC, Jerez E, Ackerman BD. Drug addiction in pregnancy and the neonate. Am J Obstet Gynecol 1976;125(2):135-42. (GRADE B, Supports Recommendation 19).
  23. Boulanger A, Clark AJ, Squire P, Cui E, Horbay GL. Chronic pain in Canada: have we improved our management of chronic noncancer pain? Pain Res Manag 2007;12(1):39-47.
  24. Boureau F, Boccard E. Placebo-controlled study of analgesic efficacy of 500mg paracetamol 30mg codeine association combined with a low dose of diclofenac versus high dose of diclofenac in rheumatoid arthritis. Acta Therapeutica 1991;17(2):123-36. (GRADE A,Supports Recommendation 4 and Recommendation 10).
  25. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: A randomized, double-blind, placebo-controlled trial. Pain 2003;104(1-2):323-31. (GRADE A,Supports Recommendation 4 and Recommendation 10).
  26. Boyd CJ, McCabe SE, Cranford JA, Young A. Adolescents' motivations to abuse prescription medications. Pediatrics 2006 Dec;118(6):2472-80. (GRADE B, Supports Recommendation 18).
  27. Brands B, Brands J. Methadone maintenance: a physicians guide to treatment. Toronto: Addiction Research Foundation; 1998.
  28. Brands B, Blake J, Sproule B, Gourlay D, Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug & Alcohol Dependence 2004 Feb 7;73(2):199-207. (GRADE B, Supports Recommendation 11).
  29. Breckenridge J, Clark JD. Patient characteristics associated with opioid versus nonsteroidal anti-inflammatory drug management of chronic low back pain. J Pain 2003;4(6):344-50. (GRADE B, Supports Recommendation 1 and Recommendation 20).
  30. Brown RT, Zuelsdorff M, Fleming M. Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. Journal of Opioid Management 2006 May;2(3):137-46.
  31. Bruera E, MacMillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39(1):13-6. (GRADE B, Supports Recommendation 7).
  32. Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Journal of Clinical Oncology 2004 Jan 1;22(1):185-92. (GRADE A, Supports Recommendation 7).
  33. Burch F, Fishman R, Messina N, Corser B, Radulescu F, Sarbu A, et al. A comparison of the analgesic efficacy of Tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. J Pain Symptom Manage 2007 Sep;34(3):328-38. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  34. Burns JM, Martyres RF, Clode D, Boldero JM. Overdose in young people using heroin: associations with mental health, prescription drug use and personal circumstances. Med J Aust 2004;181(7 Suppl):S25-S28.
  35. Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004 Nov;112(1-2):65-75.
  36. Butler SF, Benoit C, Budman SH, Fernandez KC, McCormick C, Venuti SW, et al. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006;3:5- (GRADE B, Supports Recommendation 7).
  37. Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, et al. Development and validation of the Current Opioid Misuse Measure. Pain 2007 Jul;130(1-2):144-56.
  38. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the Revised Screener and Opioid Assessment for Patients With Pain (SOAPP-R). Journal of Pain 2008;9(4):360-72.
  39. Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. Journal of Rheumatology 1999 Apr;26(4):862-9. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  40. Caldwell JR, Rapoport RJ, Davis JC, Offenberg HL, Marker HW, Roth SH, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. Journal of Pain & Symptom Management 2002 Apr;23(4):278-91. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  41. Canadian Medical Association [Internet]. Determining medical fitness to operate motor vehicles: CMA driver's guide (7th).
  42. Canadian Pharmacists Association [Internet]. Compendium of pharmaceuticals and specialties, (e-CPS) 2008.
  43. Caplehorn JR. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust 2003;179(10):557-8. (GRADE A, Supports Recommendation 21).
  44. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Annals of the Rheumatic Diseases 2008 Apr;67(4):536-41. (GRADE A, Supports Recommendation 4).
  45. Catchlove RFH, Hoirch AM. Survey of Canadian Pain Centres: a preliminary report. Pain Clinic 1988;2:231-7.
  46. Centre for Addiction and Mental Health [Internet}. Low-risk drinking guidelines 2004. Available from: About_Addiction_Mental_Health/Drug_and_Addiction_Information
  47. Chelminski PR, Ives TJ, Felix KM, Prakken SD, Miller TM, Perhac JS, et al. A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Services Research 2005 Jan 13;5(1):3. (GRADE B, Supports Recommendation 21).
  48. Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 2005 Jun;6(6):392-9. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  49. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. Journal of Pain 2009 Feb;10(2):131-46.
  50. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009 Feb;10(2):113-30.
  51. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. Journal of Pain 2006 Jan;7(1):43-8. (GRADE B, Supports Recommendation 5).
  52. Cicero TJ, Inciardi JA, Adams EH, Geller A, Senay EC, Woody GE, et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiology & Drug Safety 2005 Dec;14(12):851-9. (GRADE B,Supports Recommendation 7 and Recommendation 11).
  53. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Munoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: Researched abuse, diversion and addiction-related surveillance (RADARS ). Pain Medicine 2007;8(2):157-70. (GRADE B, Supports Recommendation 7).
  54. Cicero TJ, Lynskey M, Todorov A, Inciardi JA, Surratt HL. Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. Pain 2008 Sep 30;139(1):127-35.
  55. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Current Medical Research & Opinion 2004;(9):1419-28.
  56. Cohen J. Statistical power analysis for the behavioral sciences. 1st ed. New York,San Francisco,London: Academic press; 1988.
  57. Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH, et al. The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Regional Anesthesia & Pain Medicine 2008 May;33(3):199-206. (GRADE B, Supports Recommendation 10).
  58. College of Physicians and Surgeons of Ontario. Evidence-based Recommendations for Medical Management of Chronic Non-malignant Pain. Ontario, Canada; 2000.
  59. Compton P, Darakjian J, Miotto K. Screening for addiction in patients with chronic pain and "problematic" substance use: evaluation of a pilot assessment tool. Journal of Pain & Symptom Management 1998 Dec;16(6):355-63.
  60. Cone EJ, Fant RV, Rohay JM, Caplan YH, Ballina M, Reder RF, et al. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol 2003;27(2):57-67.
  61. Cone EJ, Fant RV, Rohay JM, Caplan YH, Ballina M, Reder RF, et al. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J Anal Toxicol 2004;28(4):217-25. (GRADE B, Supports Recommendation 6).
  62. Cook JM, Biyanova T, Thompson R, Coyne JC. Older primary care patients' willingness to consider discontinuation of chronic benzodiazepines. Gen Hosp Psychiatry 2007;29(5):396-401. (GRADE B, Supports Recommendation 6).
  63. Crisostomo RA, Schmidt JE, Hooten WM, Kerkvliet JL, Townsend CO, Bruce BK. Withdrawal of analgesic medication for chronic low-back pain patients: improvement in outcomes of multidisciplinary rehabilitation regardless of surgical history. Am J Phys Med Rehabil 2008;87(7):527-36. (GRADE B, Supports Recommendation 13).
  64. Currie SR, Hodgins DC, Crabtree A, Jacobi J, Armstrong S. Outcome from integrated pain management treatment for recovering substance abusers. Journal of Pain 2003 Mar;4(2):91-100. (GRADE B, Supports Recommendation 21).
  65. Daniell HW. DHEAS Deficiency During Consumption of Sustained-Action Prescribed Opioids: Evidence for Opioid-Induced Inhibition of Adrenal Androgen Production. Journal of Pain 7(12)()(pp 901-907), 2006 Date of Publication: Dec 2006 2006;(12):901-7. (GRADE B, Supports Recommendation 5).
  66. Dasgupta N, Kramer ED, Zalman MA, Carino S Jr, Smith MY, Haddox JD, et al. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006 Apr 28;82(2):135-42. (GRADE B,Supports Recommendation 7 and Recommendation 11).
  67. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009 Dec 8;181(12):891-6.
  68. Eccleston C. Chronic pain and distraction: an experimental investigation into the role of sustained and shifting attention in the processing of chronic persistent pain. Behavioral Research Therapy 1996;33(4):391-405.
  69. Edlund MJ, Sullivan M, Steffick D, Harris KM, Wells KB. Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? Pain Medicine 2007 Nov;8(8):647-56. (GRADE B, Supports Recommendation 1).
  70. Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain 2007 Jun;129(3):355-62. (GRADE B, Supports Recommendation 1 and Recommendation 20).
  71. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005 Jun 22;293(24):3043-52. (GRADE A, Supports Recommendation 4).
  72. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. Lancet 1999 Oct 9;354(9186):1248-52.
  73. Emkey R, Rosenthal N, Wu S-C, Jordan D, Kamin M. Efficacy and Safety of Tramadol/Acetaminophen Tablets (Ultracet) as Add-on Therapy for Osteoarthritis Pain in Subjects Receiving a COX-2 Nonsteroidal Antiinflammatory Drug: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Rheumatology 2004;31(1):150-6. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  74. Eriksen J, Ekholm O, Sjogren P, Rasmussen NK. Development of and recovery from long-term pain. A 6-year follow-up study of a cross-section of the adult Danish population. Pain 2004 Mar;108(1-2):154-62.
  75. Farney RJ, Walker JM, Cloward TV, Rhondeau S. Sleep-disordered breathing associated with long-term opioid therapy. Chest 2003 Feb;123(2):632-9. (GRADE B, Supports Recommendation 5).
  76. Farrar JT, Young JP, Jr., LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001 Nov;94(2):149-58.
  77. Farre M, Mas A, Torrens M, Moreno V, Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002;65(3):283-90. (GRADE B, Supports Recommendation 21).
  78. Federal Drug Administration. 2007 Public Health Advisories.
  79. Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2):231-41. (GRADE A, Supports Recommendation 21).
  80. Fischer B, Rehm J, Patra J. Changes in illicit opioid use across Canada. CMAJ 2006;175(11):1385-7. (GRADE B, Supports Recommendation 11).
  81. Fishbain DA, Cutler RB, Cole B, Lewis J, Rosomoff RS, Rosomoff HL. Medico-legal rounds: medico-legal issues and alleged breaches of "standards of medical care" in opioid rotation to methadone: a case report. Pain Medicine 2003 Jun;4(2):195-201.
  82. Fishbain DA, Cutler RB, Cole B, Lewis J, Smets E, Rosomoff HL, et al. Are patients with chronic low back pain or chronic neck pain fatigued? Pain Med 2004;5(2):187-95. (GRADE B, Supports Recommendation 1 and Recommendation 20).
  83. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Medicine 2008 May;9(4):444-59. (GRADE B, Supports Recommendation 1).
  84. Fishman SM, Wilsey B, Yang J, Reisfield GM, Bandman TB, Borsook D. Adherence monitoring and drug surveillance in chronic opioid therapy. Journal of Pain & Symptom Management 2000 Oct;20(4):293-307.
  85. Fishman SM, Mahajan G, Jung SW, Wilsey BL. The trilateral opioid contract. Bridging the pain clinic and the primary care physician through the opioid contract. J Pain Symptom Manage 2002 Sep;24(3):335-44. (GRADE B, Supports Recommendation 5).
  86. Fleischmann RM, Caldwell JR, Roth SH, et al. Tramadol for the treatment of join pain associated with osteoarthritis: A randomized, double-blinded, placebo-controlled trial. Current Therapeutic Research 2001;62:113-28. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  87. Fodale V, Mafrica F, Santamaria LB, Coleman JJ. Killer fentanyl: Is the fear justified? Expert Opinion on Drug Safety 2008;7(3):213-7. (GRADE B, Supports Recommendation 7).
  88. Foral PA, Ineck JR, Nystrom KK. Oxycodone accumulation in a hemodialysis patient. South Med J 2007;100(2):212-4.
  89. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008 Jan 26;336(7637):199-201. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  90. Franklin GM, Stover BD, Turner JA, Fulton-Kehoe D, Wickizer TM, Disability Risk Identification Study Cohort. Early opioid prescription and subsequent disability among workers with back injuries: the Disability Risk Identification Study Cohort. Spine 2008 Jan 15;33(2):199-204. (GRADE B, Supports Recommendation 10).
  91. Freye E, Levy JV. Use of opioids in the elderly - Pharmacokinetic and pharmacodynamic considerations. Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie 2004;39(9):527-37.
  92. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006 May 23;174(11):1589-94.
  93. Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine 2009 Aug 15;34(18):1929-41.
  94. Furlan AD, Chaparro LE, Irvin E, Mailis-Gagnon A. Opioids for chronic non cancer pain: A meta-analysis comparing enrichment and non-enrichment trial designs. Unpublished. 2010.
  95. Gana TJ, Pascual ML, Fleming RR, Schein JR, Janagap CC, Xiang J, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006 Jul;22(7):1391-401.
  96. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust 2003;179(1):38-42. (GRADE A, Supports Recommendation 21).
  97. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine 2005 Mar 31;352(13):1324-34. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  98. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. Journal of Pain & Symptom Management 2004 Aug;28(2):176-88. (GRADE B, Supports Recommendation 11).
  99. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003 Mar 25;60(6):927-34. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  100. Glowinski J, Boccard E. Placebo-controlled study of the analgesic efficacy of a paracetamol 500 mg/Codeine 30 mg combination together with low-dose vs high-dose diclofenac in rheumatoid arthritis. Clinical Drug Investigation 1999;18(3):189-97. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  101. Gobel H, Stadler TH. Treatment of pain due to postherpetic neuralgia with tramadol. Results of an open, parallel pilot study vs clomipramine with and without levomepromazine. Clinical Drug Investigation 1995;10(4):208-14. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  102. Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol 2006 Oct;74(5):908-19. (GRADE A, Supports Recommendation 6).
  103. Hadi I, da Silva O, Natale R, Boyd D, Morley-Forster PK. Opioids in the parturient with chronic nonmalignant pain: a retrospective review. Journal of Opioid Management 2006 Jan;21(1):31-4. (GRADE B, Supports Recommendation 19).
  104. Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and Safety of OPANA ER (Oxymorphone Extended Release) for Relief of Moderate to Severe Chronic Low Back Pain in Opioid-Experienced Patients: A 12-Week, Randomized, Double-blind, Placebo-controlled Study. Journal of Pain 2007 Feb;8(2):175-84. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  105. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, et al. Patterns of Abuse Among Unintentional Pharmaceutical Overdose Fatalities. JAMA 2008;(300):2613-20. (GRADE B, Supports Recommendation 11).
  106. Hanks GW, O'Neill WM, Simpson P, Wesnes K. The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. Eur J Clin Pharmacol 1995;48(6):455-60.
  107. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998 Jun;50(6):1842-6. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  108. Harke H, Gretenkort P, Ladleif HU, Rahman S, Harke O. The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. Anesthesia & Analgesia 2001 Feb;92(2):488-95. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  109. Hartikainen S, Mantyselka P, Louhivuori-Laako K, Enlund H, Sulkava R. Concomitant use of analgesics and psychotropics in home-dwelling elderly people-Kuopio 75 + study. Br J Clin Pharmacol 2005;60(3):306-10.
  110. Hendler N, Cimini C, Ma T, Long D. A comparison of cognitive impairment due to benzodiazepines and to narcotics. Am J Psychiatry 1980 Jul;137(7):828-30. (GRADE B, Supports Recommendation 7).
  111. Hermos JA, Young MM, Gagnon DR, Fiore LD. Characterizations of long-term oxycodone/acetaminophen prescriptions in veteran patients. Archives of Internal Medicine 2004 Nov 22;164(21):2361-6. (GRADE B, Supports Recommendation 6).
  112. Hooten WM, Townsend CO, Sletten CD, Bruce BK, Rome JD. Treatment outcomes after multidisciplinary pain rehabilitation with analgesic medication withdrawal for patients with fibromyalgia. Pain Med 2007 Jan;8(1):8-16. (GRADE B, Supports Recommendation 13).
  113. Howard LA, Sellers EM, Tyndale RF. The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics 2002;3(2):185-99. (GRADE C, Supports Recommendation 7).
  114. Huse E, Larbig W, Flor H, Birbaumer N. The effect of opioids on phantom limb pain and cortical reorganization. Pain 2001 Feb 1;90(1-2):47-55. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  115. IASP Task Force on Taxonomy. Part III: Pain Terms, A current List with Definitions and Notes on Usage. In: Merskey H, Bogduk N, editors. Classification of Chronic Pain. Second Edition ed. Seattle: IASP Press; 1994. p. 209-14.
  116. Ilgen MA, Trafton JA, Humphreys K. Response to methadone maintenance treatment of opiate dependent patients with and without significant pain. Drug & Alcohol Dependence 2006 May 20;82(3):187-93. (GRADE B, Supports Recommendation 21).
  117. International Narcotics Control Board. Narcotic Drugs: Estimated world requirements for 2007; Statistics for 2005. New York, NY.; 2006.
  118. International Narcotics Control Board. Narcotic Drugs: Estimated World Requirements for 2010; Statistics for 2008. New York, NY: United Nations; 2009.
  119. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996 Feb;17(1):1-12.
  120. Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine 1998 Dec 1;23(23):2591-600. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  121. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. Journal of Pain & Symptom Management 2005 Mar;29(3):297-326. (GRADE B, Supports Recommendation 21).
  122. Kahan M, Wilson L. Managing Alcohol, Tobacco and Other Drug Problems - A Pocket Guide for Physicians and Nurses. Toronto: Centre for Addiction and Mental Health; 2002.
  123. Kahan M, Srivastava A, Wilson L, Mailis-Gagnon A, Midmer D. Opioids for managing chronic non-malignant pain: safe and effective prescribing. Canadian Family Physician 2006 Sep;52(9):1091-6.
  124. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998;25(1):139-51. (GRADE B, Supports Recommendation 19).
  125. Kalvik A, Isaac P, Janecek E. Benzodiazepines: Treatment of anxiety, insomnia and alcohol withdrawal. Pharmacy Connection 1995;Sept-Oct:20-32.
  126. Kandall SR, Doberczak TM, Jantunen M, Stein J. The methadone-maintained pregnancy. Clin Perinatol 1999;26(1):173-83. (GRADE B, Supports Recommendation 19).
  127. Katz N, Rauck R, Ahdieh H, Ma T, Gerritsen vdH, Kerwin R, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007 Jan;23(1):117-28.
  128. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007 Jul;130(1-2):66-75. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  129. Kivitz A, Ma C, Ahdieh H, Galer BS. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther 2006 Mar;28(3):352-64. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  130. Kjaersgaard-Andersen P, Nafei A, Skov O, Madsen F, Andersen HM, Kroner K, et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double-blind, multi-centre study. Pain 1990 Dec;43(3):309-18. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  131. Kosinski M, Janagap C, Gajria K, Schein J, Freedman J. Pain relief and pain-related sleep disturbance with extended-release tramadol in patients with osteoarthritis. Curr Med Res Opin 2007 Jul;23(7):1615-26. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  132. Krenzelok EP. The FDA Acetaminophen Advisory Committee Meeting - what is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol (Phila) 2009 Sep;47(8):784-9. (GRADE B, Supports Recommendation 7).
  133. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 297(3):249-51, 2007 Jan 17.
  134. Lamas X, Farre M, Moreno V, Cami J. Effects of morphine in postaddict humans: a meta-analysis. Drug Alcohol Depend 1994 Oct;36(2):147-52. (GRADE B, Supports Recommendation 7).
  135. Lamb RJ, Preston KL, Schindler CW, Meisch RA, Davis F, Katz JL, et al. The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther 1991 Dec;259(3):1165-73. (GRADE B, Supports Recommendation 7 and Supports Recommendation 11).
  136. Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clin Ther 2007 Oct;29(10):2179-93. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  137. Langford R, McKenna F, Ratcliffe S, Vojtassak J, Richarz U. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 2006 Jun;54(6):1829-37. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  138. Leber PD, Davis CS. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 1998 Apr;19(2):178-87.
  139. Lee EY, Lee EB, Park BJ, Lee CK, Yoo B, Lim MK, et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial. Clin Ther 2006 Dec;28(12):2052-60. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  140. Levenson JL, McClish DK, Dahman BA, Bovbjerg VE, de AC, Penberthy LT, et al. Depression and anxiety in adults with sickle cell disease: the PiSCES project. Psychosomatic medicine 2008;70(2):192-6 (GRADE B, Supports Recommendation 1 and Recommendation 20).
  141. Lintzeris N, Ritter A, Panjari M, Clark N, Kutin J, Bammer G. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict 2004;13 Suppl 1:S29-S41. (GRADE A, Supports Recommendation 21).
  142. Ma K, Jiang W, Zhou Q, Du DP. The efficacy of oxycodone for management of acute pain episodes in chronic neck pain patients. International journal of clinical practice 2008;62(2):241-7. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  143. Madadi P, Shirazi F, Walter FG, Koren G. Establishing causality of CNS depression in breastfed infants following maternal codeine use. Paediatric Drugs 2008;10(6):399-404. (GRADE B, Supports Recommendation 19).
  144. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.[see comment]. Clinical Pharmacology & Therapeutics 2009 Jan;85(1):31-5. (GRADE B, Supports Recommendation 19).
  145. Mahowald ML, Singh JA, Majeski P. Opioid use by patients in an orthopedics spine clinic. Arthritis Rheum 2005;52(1):312-21.
  146. Maier C, Hildebrandt J, Klinger R, Henrich-Eberl C, Lindena G, MONTAS Study Group. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain - results of a double-blind placebo-controlled trial (MONTAS). Pain 2002 Jun;97(3):223-33. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  147. Man LH, Best D, Gossop M, Stillwell G, Strang J. Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment. Eur Addict Res 2004;10(1):35-40.
  148. Manchikanti L, Damron KS, Pampati V, McManus CD, Weaver SE. Prospective evaluation of patients with increasing opiate needs: Prescription opiate abuse and illicit drug use. Pain Physician 2004;7(3):339-44 (Grade B, Supports Recommendation 3).
  149. Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician 2006 Jan;9(1):57-60.
  150. Manchikanti L, Manchukonda R, Pampati V, Damron KS, Brandon DE, Cash KA, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician 2006 Apr;9(2):123-9. (GRADE B, Supports Recommendation 21).
  151. Manchikanti L, Cash KA, Damron KS, Manchukonda R, Pampati V, McManus CD. Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician 2006 Jul;9(3):215-25.
  152. Manchikanti L, Giordano J, Boswell MV, Fellows B, Manchukonda R, Pampati V. Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients. Journal of Opioid Management 2007 Mar;3(2):89-100. (GRADE B, Supports Recommendation 1 and Recommendation 20).
  153. Markenson JA, Croft J, Zhang PG, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005 Nov;21(6):524-35. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  154. Martin TL, Woodall KL, McLellan BA. Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002-2004). J Anal Toxicol 2006 Oct;30(8):603-10. (GRADE B, Supports Recommendation 7).
  155. Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 2005 Sep;6(5):357-66. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  156. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008;CD002207(April 16).
  157. Maxwell JC. Trends in the abuse of prescription drugs. Austin: The Centre for Excellence in Drug Epidemiology; 2006.
  158. McCabe SE, West BT, Morales M, Cranford JA, Boyd CJ. Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study. Addiction (Abingdon , England ) 2007;102(12):1920-30. (GRADE B, Supports Recommendation 18).
  159. McLellan AT, Turner B. Prescription Opioids, Overdose Deaths, and Physician Responsibility. JAMA 2008;300:2672-3.
  160. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain 2008 Apr;135(3):217-20.
  161. Mercadante S, Ferrera P, Villari P, Casuccio A. Rapid switching between transdermal fentanyl and methadone in cancer patients. Journal of Clinical Oncology 2005 Aug 1;23(22):5229-34. (GRADE B, Supports Recommendation 7).
  162. Michna E, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. Journal of Pain & Symptom Management 2004 Sep;28(3):250-8.
  163. Miller NS, Swiney T, Barkin RL. Effects of opioid prescription medication dependence and detoxification on pain perceptions and self-reports. American Journal of Therapeutics 2006 Sep;13(5):436-44. (GRADE B, Supports Recommendation 13).
  164. Minister of Justice. Controlled Drugs and Substance Act. Available from:
  165. Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Annals of family medicine 2007;5(2):146-50. (GRADE A, Supports Recommendation 21).
  166. Mirakbari SM, Innes GD, Christenson J, Tilley J, Wong H. Do co-intoxicants increase adverse event rates in the first 24 hours in patients resuscitated from acute opioid overdose? J Toxicol Clin Toxicol 2003;41(7):947-53. (GRADE B, Supports Recommendation 6).
  167. Mogri M, Khan MIA, Grant BJB, Mador MJ. Central sleep apnea induced by acute ingestion of opioids. Chest 2008;133(6):1484-8. (GRADE B, Supports Recommendation 5).
  168. Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O'Connor PG, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med 2007;22(4):527-30. (GRADE B, Supports Recommendation 21).
  169. Moran C. MST continus tablets and pain control in severe rheumatoid arthritis. British Jounal of Clinical Research 1991;2:1-12. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  170. Morin CM, Bastien C, Guay B, Radouco-Thomas M, Leblanc J, Vallieres A. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry 2004;161(2):332-42. (GRADE A, Supports Recommendation 6).
  171. Morley-Forster PK, Clark AJ, Speechley M, Moulin DE. Attitudes toward opioid use for chronic pain: a Canadian physician survey.[see comment]. Pain Research & Management 2003;8(4):189-94. (GRADE B, Supports Recommendation 17).
  172. Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 1999 Sep;60(9):604-12. (GRADE A, Supports Recommendation 6).
  173. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996 Jan 20;347(8995):143-7. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  174. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada--prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag 2002;7(4):179-84. (GRADE B, Supports Recommendation 17).
  175. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12(1):13-21.
  176. Myers DP, Augustyniak M, Molea J. Buprenorphine for pain management physicians: A dilemma or a therapeutic alternative? Techniques in Regional Anesthesia and Pain Management 2005;9(4):216-20. (GRADE B, Supports Recommendation 21).
  177. National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Available from: 2010.
  178. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010;(1):CD006605.
  179. Norrbrink C, Lundeberg T. Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial. Clin J Pain 2009 Mar;25(3):177-84. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  180. Nuesch E, Rutjes AW, Husni E, Welch V, Juni P. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009;(4):CD003115. (GRADE A, Supports Recommendation 4).
  181. O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998;105(2):100-5. (GRADE A, Supports Recommendation 21).
  182. Parr G, Darekar B, Fletcher A, Bulpitt CJ. Joint pain and quality of life; results of a randomised trial. British Journal of Clinical Pharmacology 1989 Feb;27(2):235-42. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  183. Pascual ML, Fleming RR, Gana TJ, Vorsanger GJ. Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain. Current Medical Research & Opinion 2007 Oct;23(10):2531-42. (GRADE B, SupportsRecommendation 10).
  184. Passik SD, Kirsh KL. Assessing aberrant drug-taking behaviors in the patient with chronic pain. Current Pain & Headache Reports 2004 Aug;8(4):289-94. (GRADE B, Supports Recommendation 11).
  185. Passik SD, Kirsh KL, Whitcomb L, Portenoy RK, Katz NP, Kleinman L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clinical Therapeutics 2004 Apr;26(4):552-61.
  186. Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. Journal of Pain & Palliative Care Pharmacotherapy 2006;20(2):5-13 (Passik 2006a).
  187. Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006 Feb;22(2):173-81 (Passik 2006b).
  188. Paulozzi LJ. Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. Am J Public Health 2006;96(10):1755-7. (GRADE B, Supports Recommendation 11).
  189. Pavelka K, Peliskova Z, Stehlikova H, Ratcliffe S, Repas C. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation 1998;16(6):421-9. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  190. Peloso PM, Bellamy N, Bensen W, Thomson GT, Harsanyi Z, Babul N, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. Journal of Rheumatology 2000 Mar;27(3):764-71. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  191. Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal N. Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. J Rheumatol 2004 Dec;31(12):2454-63. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  192. Peng P, Choiniere M, Dion D, Intrater H, Lefort S, Lynch M, et al. Challenges in accessing multidisciplinary pain treatment facilities in Canada. Canadian Journal of Anaesthesia 2007 Dec;54(12):977-84.
  193. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. Journal of Pain & Symptom Management 2001 Aug;22(2):672-87.
  194. Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Practice 2008 Jul;8(4):287-313. (GRADE B, Supports Recommendation 17).
  195. Peterson GM, Randall CT, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 1990;38(2):121-4. (GRADE B, Supports Recommendation 7).
  196. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Current Medical Research & Opinion 2007 Jan;23(1):223-33. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  197. Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 1991;27(1):7-17. (GRADE B, Supports Recommendation 7).
  198. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database of Systematic Reviews 2004;(3):CD004847. (GRADE B, Supports Recommendation 13).
  199. Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002 Oct 8;59(7):1015-21. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  200. Rajagopal A, Bruera ED. Improvement in sexual function after reduction of chronic high-dose opioid medication in a cancer survivor. Pain Med 2003 Dec;4(4):379-83. (GRADE B, Supports Recommendation 10).
  201. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manage 2003 Nov;26(5):1055-61. (GRADE B, Supports Recommendation 10).
  202. Ralphs JA, Williams AC, Richardson PH, Pither CE, Nicholas MK. Opiate reduction in chronic pain patients: a comparison of patient-controlled reduction and staff controlled cocktail methods. Pain 1994 Mar;56(3):279-88. (GRADE B, Supports Recommendation 13).
  203. Ramage-Morin PL. Medication use among senior Canadians. Health Rep 2009 Mar;20(1):37-44.
  204. Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers EL, O'Connor PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. Journal of General Internal Medicine 2002 Mar;17(3):173-9.
  205. Repchinsky C. Table 2: Opioid Analgesics. Approximate analgesic equivalences. Compendium of Pharmaceutical Specialties. Ottawa: Canadian Pharmacists Association; 2004. p. 457.
  206. Reynolds KK, Ramey-Hartung B, Jortani SA. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. Clinics in Laboratory Medicine 2008 Dec;28(4):581-98. (GRADE B, Supports Recommendation 10).
  207. Ricci JA, Stewart WF, Chee E, Leotta C, Foley K, Hochberg MC. Back pain exacerbations and lost productive time costs in United States workers. Spine 2006 Dec 15;31(26):3052-60.
  208. Riley JL, III, Hastie BA. Individual differences in opioid efficacy for chronic noncancer pain. Clin J Pain 2008;24(6):509-20.
  209. Robinson CL. Relieving pain in the elderly. Health Prog 2007 Jan;88(1):48-53, 70.
  210. Roeloffs CA, Wells KB, Ziedonis D, Tang L, Unutzer J. Problem substance use among depressed patients in managed primary care. Psychosomatics 2002;43(5):405-12.
  211. Romach MK, Otton SV, Somer G, Tyndale RF, Sellers EM. Cytochrome P450 2D6 and treatment of codeine dependence. J Clin Psychopharmacol 2000;20(1):43-5. (GRADE B, Supports Recommendation 7).
  212. Rome JD, Townsend CO, Bruce BK, Sletten CD, Luedtke CA, Hodgson JE. Chronic noncancer pain rehabilitation with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission. Mayo Clinic Proceedings 2004 Jun;79(6):759-68. (GRADE B, Supports Recommendation 10 and Supports Recommendation 13).
  213. Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug & Alcohol Dependence 2007 Sep 6;90(1):64-71. (GRADE B, Supports Recommendation 11).
  214. Roth SH. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. Journal of Rheumatology 1998 Jul;25(7):1358-63. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  215. Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Archives of Internal Medicine 2000 Mar 27;160(6):853-60. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  216. Rowbotham MC, Lindsey CD. How effective is long-term opioid therapy for chronic noncancer pain? Clinical Journal of Pain 2007;23(4):300-2. (GRADE B, SupportsRecommendation 10).
  217. Ruoff GE. Slowing the initial titration rate of tramadol improves tolerability. Pharmacotherapy 1999 Jan;19(1):88-93. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  218. Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M, Protocol CAPS. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. Clinical Therapeutics 2003 Apr;25(4):1123-41. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  219. Russell J, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. Journal of Clinical Rheumatology 2000;6(5):250-7. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  220. Salzman RT, Brobyn RD. Long-term comparison of suprofen and propoxyphene in patients with osteoarthritis. Pharmacology 1983;27 Suppl 1:55-64. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  221. Sandoval JA, Furlan AD, Mailis-Gagnon A. Oral methadone for chronic noncancer pain: a systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects. Clinical Journal of Pain 2005 Nov;21(6):503-12 (GRADE B, Supports Recommendation 7).
  222. Schein JR, Kosinski MR, Janagap-Benson C, Gajria K, Lin P, Freedman JD. Functionality and health-status benefits associated with reduction of osteoarthritis pain. Curr Med Res Opin 2008 May;24(5):1255-65.
  223. Schepis TS, Krishnan-Sarin S. Characterizing adolescent prescription misusers: a population-based study. J Am Acad Child Adolesc Psychiatry 2008;47(7):745-54. (GRADE B, Supports Recommendation 18).
  224. Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen - induced hepatotoxicity. Hepatology 2002;35(4):876-82. (GRADE B, Supports Recommendation 7).
  225. Schneider U, Bevilacqua C, Jacobs R, Karst M, Dietrich DE, Becker H, et al. Effects of fentanyl and low doses of alcohol on neuropsychological performance in healthy subjects. Neuropsychobiology 1999;39(1):38-43. (GRADE A, Supports Recommendation 7).
  226. Schnitzer TJ, Kamin M, Olson WH. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis & Rheumatism 1999 Jul;42(7):1370-7. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  227. Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. Journal of Rheumatology 2000 Mar;27(3):772-8. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  228. Schreiber S, Peles E, Adelson M. Association between improvement in depression, reduced benzodiazepine (BDZ) abuse, and increased psychotropic medication use in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend 2008;92(1-3):79-85.
  229. Seifert CF, Kennedy S. Meperidine is alive and well in the new millennium: evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy 2004 Jun;24(6):776-83. (GRADE B, Supports Recommendation 7).
  230. Seminowicz DA, Davis KD. A re-examination of pain-cognition interactions: implications for neuroimaging. Pain 2007 Jul;130(1-2):8-13.
  231. Sheather-Reid RB, Cohen M. Efficacy of analgesics in chronic pain: a series of N-of-1 studies. Journal of Pain & Symptom Management 1998 Apr;15(4):244-52. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  232. Shields LB, Hunsaker Iii JC, Corey TS, Ward MK, Stewart D. Methadone toxicity fatalities: a review of medical examiner cases in a large metropolitan area. J Forensic Sci 2007 Nov;52(6):1389-95. (GRADE B, Supports Recommendation 7).
  233. Silverfield JC, Kamin M, Wu SC, Rosenthal N, Study Group. Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. Clinical Therapeutics 2002 Feb;24(2):282-97. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  234. Silversides A. Regulatory colleges to set painkiller guidelines. CMAJ 2009 Oct 13;181(8):464-5.
  235. Simoens S, Matheson C, Bond C, Inkster K, Ludbrook A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract 2005;55(511):139-46. (GRADE B, Supports Recommendation 21).
  236. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007 Apr;29(4):588-601. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  237. Sims SA, Snow LA, Porucznik CA. Surveillance of methadone-related adverse drug events using multiple public health data sources. Journal of biomedical informatics 2007;40(4):382-9. (GRADE B, Supports Recommendation 7).
  238. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999 Oct;83(1):85-90. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  239. Solomon DH, Avorn J, Wang PS, Vaillant G, Cabral D, Mogun H, et al. Prescription opioid use among older adults with arthritis or low back pain. Arthritis & Rheumatism 2006 Feb 15;55(1):35-41. (GRADE B, Supports Recommendation 17).
  240. Sproule B, Brands B, Li S, Catz-Biro L. Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. Canadian Family Physician 2009 Jan;55(1):68-9.
  241. Staud R, Price DD. Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. Pain 2008 Jun;136(3):232-4.
  242. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med 2005;20(11):1038-41.
  243. Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003;326(7396):959-60. (GRADE B, Supports Recommendation 21).
  244. Sullivan MD, Edlund MJ, Steffick D, Unutzer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain 2005 Dec 15;119(1-3):95-103 (GRADE B, Supports Recommendation 1, Recommendation 6 and Recommendation 20).
  245. Sullivan MD, Edlund MJ, Zhang L, Unutzer J, Wells KB. Association between mental health disorders, problem drug use, and regular prescription opioid use. Archives of Internal Medicine 2006 Oct 23;166(19):2087-93.
  246. Tegeder I, Geisslinger G, Lotsch J. Therapy with opioids in liver or renal failure. Schmerz 1999;13(3):183-95.
  247. Thorne C, Beaulieu AD, Callaghan DJ, O'Mahony WF, Bartlett JM, Knight R, et al. A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis. Pain Res Manag 2008 Mar;13(2):93-102. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  248. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006 Apr;7(4):281-9.
  249. Townsend CO, Kerkvliet JL, Bruce BK, Rome JD, Hooten WM, Luedtke CA, et al. A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission. Pain 2008;140(1):177-89. (GRADE B, Supports Recommendation 20).
  250. Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer TR, Abdi S, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006 Jan;9(1):1-39.
  251. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008 Mar;11(2 Suppl):S5-S62.
  252. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician 2008 Mar;11(2 Suppl):S181-S200.
  253. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clinical Journal of Pain 2008 Jul;24(6):497-508.
  254. Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997;7(5):375-9. (GRADE B, Supports Recommendation 7).
  255. Utah Department of Health. Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain.  2009. Available from:
  256. Vicens C, Fiol F, Llobera J, Campoamor F, Mateu C, Alegret S, et al. Withdrawal from long-term benzodiazepine use: randomised trial in family practice. Br J Gen Pract 2006;56(533):958-63. (GRADE B, Supports Recommendation 6).
  257. Vlok GJ, van Vuren JP. Comparison of a standard ibuprofen treatment regimen with a new ibuprofen/paracetamol/codeine combination in chronic osteo-arthritis. South African Medical Journal 1987 Oct 17;1(Suppl 1-6):- (GRADE A, Supports Recommendation 4 and Recommendation 10).
  258. Voaklander DC, Rowe BH, Dryden DM, Pahal J, Saar P, Kelly KD. Medical illness, medication use and suicide in seniors: a population-based case-control study. Journal of epidemiology and community health 2008;62(2):138-46. (GRADE B, Supports Recommendation 20).
  259. Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008 Dec;9(12):1144-54.
  260. Vorsanger GJ, Xiang J, Gana TJ, Pascual ML, Fleming RR. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag 2008 Mar;4(2):87-97. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  261. Walker JM, Farney RJ, Rhondeau SM, Boyle KM, Valentine K, Cloward TV, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. Journal of Clinical Sleep Medicine 2007 Aug 15;3(5):455-61. (GRADE B, Supports Recommendation 10).
  262. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR, Jr. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 2008;98(3):191-202. (GRADE B, Supports Recommendation 7).
  263. Wang EC. Methadone treatment during pregnancy. J Obstet Gynecol Neonatal Nurs 1999;28(6):615-22. (GRADE B, Supports Recommendation 19).
  264. Wasan AD, Davar G, Jamison R. The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain 2005 Oct;117(3):450-61. (GRADE B, Supports Recommendation 1 and Recommendation 20).
  265. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998 Jun;50(6):1837-41. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  266. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003 Sep;105(1-2):71-8. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  267. Weaver M, Schnoll S. Addiction Issues in Prescribing Opioids for Chronic Nonmalignant Pain. J Addict Med 2007;1:2-10.
  268. Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. Spine 2007 Sep 1;32(19):2127-32. (GRADE B, Supports Recommendation 10).
  269. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Medicine 2005 Nov;6(6):432-42. (GRADE B, Supports Recommendation 2).
  270. Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex Minimizes Physical Dependence While Providing Effective Analgesia: A Randomized Controlled Trial in Low Back Pain. Journal of Pain 2006 Dec;7(12):937-46. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  271. Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. Pain Medicine 2008 May;9(4):425-32. (GRADE B, Supports Recommendation 10).
  272. Wenghofer E, Wilson L, Kahan M, Srivastava A. A survey of Ontario primary care physicians' experiences with opioid prescribing. 2009.
  273. West SL, O'Neal KK, Graham CW. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 2000;12(4):405-14.
  274. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction (Abingdon , England ) 1999;94(7):961-72.
  275. Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Medicine 2007 Oct;8(7):573-84. (GRADE B, Supports Recommendation 21).
  276. Wilder-Smith OHG. Opioid use in the elderly. European Journal of Pain 2005;9(2 SPEC. ISS.):137-40.
  277. Wilsey BL, Fishman SM, Tsodikov A, Ogden C, Symreng I, Ernst A. Psychological comorbidities predicting prescription opioid abuse among patients in chronic pain presenting to the emergency department. Pain Medicine 2008 Nov;9(8):1107-17. (GRADE B, Supports Recommendation 1 and Recommendation 20).
  278. Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol 1990;43(9):891-905.
  279. Wu CL, Agarwal S, Tella PK, Klick B, Clark MR, Haythornthwaite JA, et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo-controlled, crossover trial. Anesthesiology 2008 Aug;109(2):289-96. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  280. Wu SM, Compton P, Bolus R, Schieffer B, Pham Q, Baria A, et al. The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. Journal of Pain & Symptom Management 2006 Oct;32(4):342-51.
  281. Ytterberg SR, Mahowald ML, Woods SR. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis & Rheumatism 1998 Sep;41(9):1603-12.
  282. Zacny JP, Lichtor JL, Zaragoza JG, de Wit H. Subjective and behavioral responses to intravenous fentanyl in healthy volunteers. Psychopharmacology (Berl) 1992;107(2-3):319-26. (GRADE A, Supports Recommendation 7).
  283. Zacny JP, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology (Berl) 2003 Nov;170(3):242-54. (GRADE A,Supports Recommendation 8 and Recommendation 11 ).
  284. Zacny JP, Gutierrez S, Bolbolan SA. Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users. Drug Alcohol Depend 2005 Jun 1;78(3):243-52. (GRADE A, Supports Recommendation 8).
  285. Zacny JP, Lichtor SA. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology (Berl) 2007;196(1):105-16. (GRADE B, Supports Recommendation 8).
  286. Zautra AJ, Smith BW. Impact of controlled-release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clin J Pain 2005 Nov;21(6):471-7. (GRADE A, Supports Recommendation 4 and Recommendation 10).
  287. Zgierska A, Brown RT, Zuelsdorff M, Brown D, Zhang Z, Fleming MF. Sleep and daytime sleepiness problems among patients with chronic noncancerous pain receiving long-term opioid therapy: a cross-sectional study. Journal of Opioid Management 2007 Nov;3(6):317-27. (GRADE B, Supports Recommendation 5).